If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
72.50    0.50 (0.69%)
Bid:
72.00
Ask:
73.00
Spread: 1.00 (1.389%)
Market Cap: £342.04m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Issue of Equity

6 Jan 2015 07:00

RNS Number : 3456B
Avacta Group PLC
06 January 2015
 



 

Avacta Group plc

("Avacta", the "Group" or the "Company")

 

Issue of Equity

 

Avacta Group plc (AIM: AVCT), a global provider of research reagents, consumables and equipment to the life sciences and animal care markets, today announces that 7,500,000 Ordinary Shares of 0.1p ("new Ordinary Shares") have been issued by the Company pursuant to the exercise of share options.

 

Application has been made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 9 January 2015.

 

The total number of Ordinary Shares in issue following the above issue will be 4,975,149,550 each with voting rights. No Ordinary Shares are held in Treasury.

 

The above figure of 4,975,149,550 shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

 

 

Avacta Group plc

www.avacta.com

Alastair Smith, Chief Executive Officer

Tel: +44 (0) 844 414 0452

Tim Sykes, Chief Financial Officer

 

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Corporate Broking)

 

Walbrook PR Limited

Tel: +44 (0) 20 7933 8780 or avacta@walbrookpr.com

Mike Wort

Mob: +44 (0)7900 608 002

Anna Dunphy

Mob: +44 (0)7876 741 001

 

Avacta Group plc is a global provider of research reagents, consumables and equipment to the life sciences and animal care. Avacta operates through three divisions:

 

Avacta Life Sciences

www.avactalifesciences.com

 

Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development.

Avacta Animal Health

www.avactaanimalhealth.com

 

Veterinary diagnostics reference laboratory services, SensiTest, and diagnostic kits, SensiPak.

Avacta Analytical

www.avactaanalytical.com

 

High throughput analysis instrument, Optim, to help reduce the cost and risk of drug development.

 

Avacta joined AIM in August 2006 and is based in Wetherby, England.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEUVVKRVAAARAR
Date   Source Headline
21st Jul 20257:00 amRNSPayment of Convertible Bond Installment
17th Jul 20257:00 amRNSEquity fundraise of £3.25 million
2nd Jul 20255:00 pmRNSResult of AGM
2nd Jul 20257:00 amRNSQ2 2025 Business Update
1st Jul 20257:00 amRNSManagement Team Appointments
30th Jun 20253:00 pmRNSAppointment of Zeus Capital as Joint Broker
19th Jun 20257:00 amRNSNew Response in Phase 1b Trial
9th Jun 20255:15 pmRNSPosting of Annual Report and Revised Notice of AGM
6th Jun 20257:00 amRNSPreliminary Full Year 2024 Results
4th Jun 20257:00 amRNSAvacta Change in Prelim Date Part 2
28th May 20257:00 amRNSBoard appointments
27th May 20257:00 amRNSUpdate on timing of preliminary results
15th May 20257:00 amRNSNotice of Results
12th May 202512:00 pmRNS-RInvestor Webinar
8th May 20257:30 amRNSBlock Listing Application to AIM
29th Apr 20257:00 amRNSBoard change
28th Apr 20255:52 pmRNSBlock Listing Six Monthly Return
28th Apr 20257:01 amRNSAvacta presents preclinical data at AACR
28th Apr 20257:00 amRNSAvacta presents data from lead candidate at AACR
23rd Apr 20257:00 amRNSIssue of Equity and Total Voting Rights
31st Mar 20257:00 amRNSAvacta Quarterly Update
26th Mar 20257:00 amRNSAvacta Announces Presentations at AACR
25th Mar 20257:00 amRNSAvacta Completes Launch Diagnostics Sale
10th Mar 20257:00 amRNSAvacta to Present at Leerink Healthcare Conference
7th Mar 20258:40 amRNSAvacta announces data update for AVA6000
7th Mar 20257:42 amRNSAvacta to sell Launch Diagnostics
4th Feb 20257:00 amRNSAppointment of Joint Broker
21st Jan 20253:09 pmRNSIssue of Equity and Total Voting Rights
16th Jan 20257:00 amRNSAvacta Announces Data from AVA6000 Phase 1 trial
13th Jan 20257:00 amRNSAvacta Appoints Chief Financial Officer
12th Dec 20247:00 amRNSCompletion of Dose Escalation and RDE Arms
30th Oct 20247:00 amRNSR&D Spotlight focusing on pipeline advances
28th Oct 20247:00 amRNSBlock Listing Six Monthly Return
24th Oct 20247:00 amRNSAvacta Reports Pipeline Avances at EORTC
21st Oct 20244:00 pmRNSIssue of Equity and Total Voting Rights
21st Oct 20247:00 amRNSAvacta and Tempus Enter Strategic Collaboration
17th Oct 20247:00 amRNSAvacta Expands its Pipeline
15th Oct 20247:00 amRNSAvacta appoints Chief Scientific Officer
10th Oct 20247:00 amRNSAvacta Unveils Pipeline Expansion at EORTC 2024
30th Sep 20247:00 amRNSInterim Results
16th Sep 20247:00 amRNSAvacta Reported Updated Phase 1 Data of AVA6000
12th Sep 20247:00 amRNSNotice of Results
9th Sep 20247:00 amRNSAvacta to present clinical data at ESMO Congress
2nd Sep 20243:53 pmRNSDirector/PDMR Shareholdings and TVR
18th Jul 20247:00 amRNSConvertible Bond Payment
26th Jun 20242:46 pmRNSResult of AGM
26th Jun 20247:00 amRNSAGM Business Update
20th Jun 20247:00 amRNSShaun Chilton appointed Non-Executive Chairman
11th Jun 20247:00 amRNSAppointment of Nominated Adviser and Sole Broker
31st May 20247:00 amRNSPosting of Annual Report and Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.